普萘洛尔治疗婴幼儿血管瘤的临床疗效及安全性研究

Clinical efficacy and safety of propranolol on infantile hemangioma

目的观察口服普萘洛尔治疗婴幼儿血管瘤的近期疗效与安全性。方法选取120例婴幼儿血管瘤患儿采用口服普萘洛尔治疗作为观察组,首次剂量为0.5 mg/kg;同时选取60例采用尿素局部注射治疗的血管瘤患儿作为对照组。随访1年。采用A chaner提出的四级标准进行疗效评价。结果观察组总有效率为94.17%。对照组自行消退总有效率为38.33%,观察组疗效明显优于对照组,两组比较差异具有统计学意义(P<0.05)。观察组患儿中,5例出现消化道不适,4例血钾升高,12例心动过缓,6例出现低血压,4例表现为兴奋及睡眠减少,不良反应经对症处理消失或自行消失,未出现低血糖及肝肾功能损害等严重不良反应。结论小剂量口服普萘洛尔治疗婴幼儿血管瘤可使瘤体体积缩小,颜色变浅,近期疗效良好,不良反应轻微,患儿可耐受。

Objective To observe the clinical efficacy and safety of oral propranolol treatment on infantile hemangioma.Methods 120 cases of infantile hemangioma were treated with oral propranolol （observation group）,the first dose of 0.5 mg/kg,60 patients were given local injection of urea （control group）,the two groups were followed up for one year,The effect was evaluated using A chaner proposed four standards for efficacy evaluation.Results The total effective rate of observation group was higher than that of control group（94.17％ vs.38.33％,P ＜0.05）.There were 5 cases of gastrointestinal discomfort,4 cases of elevated serum potassium,12 cases of bradycardia,6 cases of hypotension,4 cases manifested as excited and sleep loss with no hypoglycemia and liver and kidney dysfunction and other serious side effects.Conclusion The low-dose oral propranolol treatment for infantile hemangioma tumor can shrink the tumor,lighter colors with a good short-term efficacy and mild adverse reactions,and the children are tolerated.